Inflammation dysregulation in placenta is implicated in the pathogenesis of numerous pregnancy complications. Glucocorticoids (GCs), universally considered anti-inflammatory, can also exert proinflammatory actions under some conditions, whereas whether and how GCs promote placental inflammation have not been intensively investigated. In this paper we report the opposing regulation of rat placental inflammation by synthetic GC dexamethasone (Dex). When Dex was subcutaneously injected 1 h after we administered an intraperitoneal lipopolysaccharide (LPS) challenge, neutrophil infiltration and proinflammatory Il1b, Il6, and Tnfa expression in rat placenta were significantly reduced. In contrast, Dex pretreatment for 24 h potentiated rat placental proinflammatory response to LPS and delayed inflammation resolution, which involved MAPKs and NF-kappaB activation. Mechanically, Dex pretreatment promoted 5-lipoxygenase (ALOX5) activation and increased leukotriene B 4 production, whereas it inhibited the anti-inflammatory and proresolving lipid mediator lipoxin A 4 (LXA 4 ) biosynthesis in rat placenta via downregulating ALOX15 and ALOX15B expression. Moreover, LXA 4 supplementation dampened Dex-potentiated placental inflammation and suppressed Dex-mediated ALOX5 activation in vivo and in vitro. Taken together, these findings suggest that GCs exposure could promote placental inflammation initiation and delay resolution via disrupting LXA 4 biosynthesis.
INTRODUCTION
Upon pregnancy challenge, the maternal immune system must adapt to tolerate the growing fetus-placenta within the uterus as well as defend against pathogens, for a successful outcome [1] [2] [3] . Disturbance of the delicate immune balance may result in pregnancy disorders, including pregnancy loss and pre-eclampsia (PE) [1, 2, 4] . During pregnancy, placenta can be exposed to glucocorticoids (GCs) in several ways, including maternal stress, synthetic GC administration, and cortisol metabolism damage [5, 6] . GC exposure may be implicated in obstetric complications, including preterm labor, intrauterine growth restriction (IUGR) and PE [5] . Indeed, we recently reported that abnormal GC metabolism is responsible for spontaneous miscarriages [6] . We also showed that GC exposure could induce IUGR in rats [7] . GCs, universally considered anti-inflammatory [8] , can also display proinflammatory actions under some conditions [9, 10] . For instance, GC pretreatment increased LPS-stimulated interleukin 6 (IL6) and tumor necrosis factor (TNF) expression in human plasma [11] , which is consistent with the results obtained in the stresschallenged rat model [12] .
The resolution of inflammation is an active process in response to stimuli, which drives immunity to result in timely tissue restoration and return of homeostasis [13] . Lipoxins (LXs), bioactive products derived from arachidonic acid (AA) enzymatically by lipoxygenase (ALOX) and prostaglandinendoperoxide synthase (PTGS; also known as cyclooxygenase), function as ''stop signals'' in inflammation, which exert dual anti-inflammatory (inhibition of neutrophils and eosinophils infiltration) and proresolving (promotion of efferocytosis of apoptotic neutrophils) actions [14] . LXs also play vital roles in inflammation termination and homoeostasis restoration of reproductive system [15] . For instance, Lipoxin A 4 (LXA 4 ) inhibits LPS-stimulated proinflammatory IL6 and IL8 expression in human endometrium and deciduas [16, 17] . Recently, we found that LXA 4 alleviated TNF and IL8 levels in LPS-induced rat PE [18] . We also reported that LXA 4 prevented LPS-induced miscarriages in mouse via antagonizing LPSinduced proinflammatory Il6 and IFNG and promoting antiinflammatory IL10 production [6] .
Although the adverse effects of GCs on pregnancy have been extensively investigated, the effects of GCs on placental inflammatory balance remain largely unclear. Given the controversial actions of GCs in modulating inflammatory responses, the purpose of the present study was to test the hypothesis that prior exposure to synthetic GC dexamethasone (Dex) exacerbates, rather than inhibits, rat placental inflammatory responses to peripheral immunologic challenge (LPS). Furthermore, we examined whether Dex-mediated sensitization of placental inflammatory responses is explained by the dysregulation of AA-derived bioactive lipid mediator biosynthesis, particularly LXA 4 production. The LXA 4 modulation of Dex-mediated trophoblast 5-LOX activation was also investigated both in vivo and in vitro.
MATERIALS AND METHODS

Reagents and Antibodies
LPS (Escherichia coli serotype O127:B8), Dex (for cell experiments), Dex sodium phosphate (for animal experiments), and RU486 were purchased from Sigma-Aldrich. A stock solution of LXA 4 (Cayman Chemical) was stored at À808C until being diluted in sterile 0.9% saline or cell culture medium immediately before use. Boc2 (N-t-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe) was from GenScript. Anti-IjB-a, -IKKa, -NF-jB p65, -ALOX12, -ALOX15, -ALOX15B, -b-actin, and -lamin B antibodies were from Santa Cruz Biotechnology. Anti phospho-MAPKs, MAPKs, phospho-IKKa/b, and phospho-IjBa were obtained from Cell Signaling Technology. Mouse ALOX5 monoclonal antibody (BD Biosciences) was used for Western blotting and immunofluorescence, whereas rabbit ALOX5 polyclonal antibody (Cayman Chemical) was used for immunohistochemistry (IHC). ProteoJET mammalian cell lysis reagent was from Fermentas. NE-PER nuclear and cytoplasmic extraction reagents kit, bicinchoninic acid (BCA) protein assay kit and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse secondary antibody were from Pierce. TRIzol was purchased from Life Technologies.
Animals and Experimental Treatment
Female Sprague-Dawley rats (10-12 wk old, weighing 220-250 g) were from the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. Animals were housed individually in plastic cages with wood chips as bedding, under pathogen-free conditions, at 20-258C, and 12L:12D. Rats were fed a standard laboratory diet and water ad libitum. Pregnancy was obtained by mating female rats with fertile male rats at a ratio of 2:1 overnight. Daily vaginal smears were observed, and appearance of spermatozoa in a vaginal smear was defined as Gestational Day (GD) 1. All animal work was conducted according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All studies involving rats were approved by Animal Care and Use Committee of Huazhong University of Science and Technology.
Animal protocol 1: Dex and LPS infusion. Pregnant rats were randomly divided into control and treatment groups (n ¼ 6 in each group). Rats were injected i.p. with LPS (50 lg/kg) or vehicle (saline) on GD14. Dex (5 mg/kg) or vehicle (saline) was administered s.c. under the following conditions: Dex 1 h post-LPS and Dex 24 h pre-LPS. According to different endpoints, the Dex 24 h pre-LPS group was further divided into Dex 24 h pre-LPS 1 and Dex 24 h pre-LPS 2. For Dex 1 h post-LPS and Dex 24 h pre-LPS 1 experiments, placenta tissues were collected at 4 h post-LPS administration. For Dex 24 h pre-LPS 2, placenta tissues were collected at 24 h post-LPS administration. These treatment conditions were selected to determine whether the timing of Dex administration relative to that of LPS could determine opposite actions of GCs in modulating placental inflammatory response and whether Dex could cause delayed resolution of placental inflammation.
Animal protocol 2: Dex infusion in different doses. Rats in treatment groups (n ¼ 6 in each group) were injected s.c. with different doses of Dex (2.5, 5, 10, and 20 mg/kg) on GD13. Control rats (n ¼ 6) were infused with equal amounts of vehicle saline. At 24 h post-Dex or vehicle administration, placenta tissues were collected for different analyses. This experiment was carried out to determine whether Dex pretreatment could disturb AA metabolism and LXA 4 biosynthesis in placenta.
Animal protocol 3: LXA 4 treatment post Dex and LPS infusion. Pregnant rats were randomly divided into control and treatment groups (n ¼ 6 in each group). Treatment rats were injected s.c. with Dex (5 mg/kg) on GD13. One hour later, the rats were injected i.p. with LXA 4 (10 lg/kg); 23 h post-LXA 4 injection, the rats were injected i.p. with LPS (50 lg/kg). At 4 h and 24 h post-LPS administration, placenta tissues were collected for different analyses. This experiment was designed to determine whether LXA 4 could inhibit the sensitization of Dex on placental proinflammatory response to peritoneal immunologic challenge (LPS).
Animal protocol 4: LXA 4 treatment post Dex infusion. Pregnant rats were randomly divided into control group (n ¼ 6), Dex group (n ¼ 6), and DexþLXA 4 group (n ¼ 6). Rats in the Dex and DexþLXA 4 groups were infused s.c. with Dex (5 mg/kg) on GD13, whereas rats in control group were injected s.c. with equal vehicle. After 1 h, rats in DexþLXA 4 group were injected i.p. with LXA 4 (10 lg/kg), whereas rats in control and Dex groups were injected with equal amounts of vehicle. At 23 h post-LXA 4 or vehicle administration, placenta tissues were collected for different analyses. The LXA 4 treatment post-Dex was applied to determine whether LXA4 could suppress Dex-mediated activation of placental ALOX5 pathway.
Tissue Collection
At indicated times in each group, rats were fully anesthetized with chloral hydrate and the uterus was removed and placed in a chilled dish. The individual placenta was rapidly extracted and placed on ice. All samples were analyzed individually. For histological evaluation, placentas were fixed in neutralbuffered formalin.
Cell Culture and Treatment
Human first-trimester trophoblast HTR8/SVneo cell line was a gift from Dr. Charles H. Graham (Queen's University, Kingston, ON, Canada). Cells were cultured at 378C in a humidified atmosphere with 5% CO 2 in Dulbecco modified Eagle medium/F-12 medium (Gibco) supplemented with 10% heatinactivated fetal bovine serum (Gibco), 25 mM HEPES, 100 U/ml penicillin G, and 100 U/ml streptomycin. Cells were plated in 6-well plates or on glass coverslips in 12- 
Hematoxylin and Eosin Staining and IHC
Hematoxylin and eosin (H&E) staining was performed with 4-lm paraffin sections of placenta specimens for evaluation of neutrophil infiltration under light microscopy (Olympus model BX60). Counting of neutrophils was performed in three randomly selected microscopic fields of the junctional zone in placenta at a magnification of 3400. The mean number of neutrophils per field from six rat placentas was used for data analysis.
For assessment of placental ALOX5 expression and location, regular IHC assay was performed. Briefly, paraffin (4-lm) sections of placenta specimens were cut, and after deparafinization, antigen retrieval was performed in sodium citrate solution (pH 6). Sections were incubated with rabbit anti-ALOX5 primary antibody (1:100 dilution) or rabbit nonimmune serum at 48C overnight. Sections were then washed and incubated with secondary antibody for 45 min at room temperature. The sections were subsequently incubated with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB) substrate, lightly counterstained with hematoxylin, dehydrated, and mounted.
RNA Isolation and Real-Time PCR
Total RNA was isolated from placenta tissues using TRIzol reagent according to the manufacturer's protocol. The concentration and purity of total RNA were determined by using an ultraviolet spectrophotometer (Eppendorf). Complementary DNA synthesis was performed using the ReverTra Ace cDNA synthesis kit (Toyobo) according to the manufacturer's instructions. Quantitative PCR analysis was carried out with a CFX Connect real-time PCR detection system using iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). Each sample was quantified in triplicate (n ¼ 3). PCR conditions were 30 sec at 958C, followed by 40 cycles of 10 sec at 958C and 20 sec at 608C. Relative gene expression was determined using the 2 ÀDDC T method [19] , whereby expression data for each sample were normalized to that of internal control Gapdh and expressed as the fold change compared to untreated controls. Data were analyzed using CFX Manager 2.1 software (Bio-Rad Laboratoried). Primers used in this study are listed in Table 1. ZHANG ET AL.
Western Blotting
Total and nuclear proteins were extracted using ProteoJET mammalian cell lysis reagent and NE-PER nuclear and cytoplasmic extraction reagent, respectively. Protein concentrations were determined using a BCA protein assay kit. Equal amounts of protein (40 lg) were then subjected to 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore). Different primary antibodies were incubated with the membranes overnight at 48C. b-Actin or lamin B served as internal control. The bound antibody was detected by an enhanced chemiluminescence kit (Millipore) on x-ray film.
Determination of LXA 4 , Leukotriene B 4 , and Prostaglandin E 2
Before measurement of placental LXA 4 , leukotriene B 4 (LTB 4 ), and prostaglandin E 2 (PGE 2 ) concentrations, tissue homogenization was performed to extract the tissue contents in placenta. Briefly, placenta samples were homogenized in mild homogenate buffer containing a cocktail enzyme inhibitor, by using the glass homogenizer. Twenty minutes later, homogenate samples were centrifuged at 3000 rpm at 48C for 20 min. Supernatants were then collected and stored at À808C until determination. Levels of LXA 4 , LTB 4 , and PGE 2 in placenta were assessed by ELISA according to manufacturers' protocols (Neogen Corp.; Cayman Chemical).
Immunofluorescence
Regular immunofluorescence assay was performed to detect cellular ALOX5 expression and location. Mouse anti-ALOX5 primary antibody (1:100 dilution) and FITC-conjugated goat anti-mouse secondary antibody (1:100 dilution) were applied. Cell nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole. Fluorescence images were processed using LSM710 and ConfoCor3 microscope systems (Carl Zeiss).
Statistical Analysis
All statistical analyses were done using SPSS version 19.0 software (SPSS). Results are means 6 SEM of multiple independent experiments. The means of the different groups were compared by using one-way ANOVA. A P value of ,0.05 was considered significant.
RESULTS
Prior Exposure to Dex Sensitizes Placental Proinflammatory Response to LPS
We first administered Dex s.c. 1 h post-LPS intraperitoneal challenge (see Dex 1 h post-LPS in Fig. 1A ). LPS (50 lg/kg) significantly increased neutrophil infiltration in placental junctional zone ( Fig. 1B ; P , 0.001) and Il1b (P , 0.001), Il6 (P , 0.001), and Tnfa (P , 0.001) expression levels in placenta (Fig. 1C) . Dex (5 mg/kg) significantly suppressed LPS-triggered neutrophil infiltration ( Fig. 1B ; P , 0.01) and blunted proinflammatory cytokine Il1b (P , 0.01), Il6 (P , 0.01), and Tnfa (P , 0.001) expression compared to that in the LPS group (Fig. 1C) . In addition, LPS did not alter Il10 expression, whereas Dex treatment post-LPS challenge increased Il10 expression compared to that in the control (P , 0.05) and LPS (P , 0.05) groups (Fig. 1C) .
We next administered Dex 24 h prior to LPS (see Dex 24 h pre-LPS 1 in Fig. 1A ). Of interest, this retrograde shift in the administration of Dex revealed a very different pattern of inflammatory response. Dex (5 mg/kg) pretreatment enhanced LPS (50 lg/kg)-stimulated neutrophil infiltration in junctional zone ( Fig. 1B ; P , 0.05) and Il1b (P , 0.001), Il6 (P , 0.01), and Tnfa (P , 0.01) expression (Fig. 1C) . However, Dex failed to potentiate Il10 expression (Fig. 1C) . Dex alone even caused a significant reduction in Il10 ( Fig. 1C ; P , 0.001). Then we selected 24 h as the observation endpoint (see Dex 24 h pre-LPS 2 in Fig. 2A ), Dex (5 mg/kg) also aggravated neutrophil infiltration ( Fig. 2B ; P , 0.05) and proinflammatory cytokines Il1b (P , 0.001), Il6 (P , 0.001) and Tnfa (P , 0.01) expression (Fig. 2C) induced by 50 lg/kg LPS. Moreover, LPS enhanced anti-inflammatory Il10 expression at the delayed endpoint ( Fig. 2C ; P , 0.001), whereas Dex pretreatment significantly attenuated LPS-stimulated Il10 expression ( Fig.  2C ; P , 0.001). Dex alone also reduced Il10 expression at this delayed endpoint ( Fig. 2C ; P , 0.001). Together, these results demonstrate the opposing regulation of LPS-triggered placental inflammation by GCs according to different administration time relative to peritoneal LPS challenge.
Dex Pretreatment Potentiates LPS-Triggered MAPKs and NF-jB in Placenta
Because MAPKs and NF-jB pathways are important signals in inflammatory processes [20, 21] , we examined their expression levels in both the Dex 24 h pre-LPS 1 and Dex 24 h pre-LPS 2 experiments. In Dex 24 h pre-LPS 1, LPS significantly increased the expression of p-ERK (P , 0.001), p-P38 (P , 0.001), p-JNK (P , 0.001), p-IKKa/b (P , 0.001), p-IjBa (P , 0.001), and NF-jB p65 (P , 0.001), and reduced IjBa (P , 0.001) expression in placenta (Fig. 3, A  and B) . Of interest, Dex pretreatment failed to blunt LPStriggered MAPKs and NF-jB (Fig. 3, A and B) . In Dex 24 h pre-LPS 2, LPS significantly upregulated the levels of p-ERK (P , 0.001), p-P38 (P , 0.001), p-JNK (P , 0.01), p-IKKa/b (P , 0.001), p-IjBa (P , 0.01), and NF-jB p65 (P , 0.001) and attenuated IjBa expression (P , 0.05) (Fig. 3, C and D) . However, Dex even enhanced MAPKs and NF-jB induced by LPS at the delayed endpoint (Fig. 3, C and D) . These findings suggest that activation of MAPKs and NF-jB pathways are involved in Dex-mediated potentiation of LPS-triggered placental proinflammatory response. Previous studies have shown that microbial infection could induce endogenous LXA 4 biosynthesis for terminating proinflammatory response in vivo [22, 23] . Given the enhanced neutrophil infiltration and proinflammatory cytokine expression levels in placenta, we questioned the regulation of LXA 4 production by Dex during the sensitization process. As shown in Figure 4A , Dex dose-dependently reduced placental LXA 4 production, with a maximal reduction observed at 20 mg/kg (P , 0.01).
To determine whether LPS could induce LXA 4 synthesis in placenta and to further address the effect of Dex on LXA 4 production, we assessed the LXA 4 levels in placenta in both the Dex 24 h pre-LPS 1 and Dex 24 h pre-LPS 2 experiments. In Dex 24 h pre-LPS 1, LXA 4 levels were not significantly changed by either LPS or Dex plus LPS (Fig. 4B) . However, in Dex 24 h pre-LPS 2, LPS significantly increased LXA 4 levels in placenta compared to that in control ( Fig. 4C ; P , 0.05). In contrast, Dex pretreatment significantly attenuated LPSinduced LXA 4 production compared to that in LPS alone ( Fig. 4C; P , 0.001 ). These results demonstrate that Dex inhibits LXA 4 production in placenta. ALOX5 or ALOX5 and ALOX12 [14] . ALOX15 exists in two isoforms: ALOX15 and ALOX15B [15] . ALOX15 oxygenates AA at both carbon 12 and 15, whereas ALOX15B converts AA exclusively to 15 (S)-HETE [24] . Recently, Russell et al. [25] showed that ALOX15B is present in endometrial tissue, whereas Jones et al. [26] identified the ALOX15B expression in placenta. In the present study, Dex (5-20 mg/kg) downregulated the gene and protein expression levels of both ALOX15 and ALOX15B in placenta (Fig. 5, A, B, and D) . However, Dex failed to reduce ALOX5 expression in placenta and instead upregulated ALOX5 mRNA and protein at doses of 5-20 mg/kg (Fig. 5, C and D) . The nuclear translocation of ALOX5 was also increased after Dex treatment (Fig. 5D) . Moreover, IHC results indicated that Dex (5-20 mg/kg) significantly increased ALOX5 expression in placenta tissue, especially in trophoblast nuclei (Fig. 5E ). Because ALOX5 is the key enzyme for the biosynthesis of both proinflammatory leukotrienes (LTs) and proresolving LXs, we questioned whether Dex-mediated ALOX5 activation contributed to enhanced LTB 4 formation. As shown in Figure 5F , Dex significantly increased LTB 4 production in placenta with a maximal increase observed at 5 mg/kg (P , 0.01). In addition, we examined the modulation of ALOX12 by Dex. Unexpectedly, Dex significantly increased ALOX12 gene and protein expression in placenta at doses of 2.5-20 mg/kg (Supplemental Fig. S1 , A and B; all Supplemental Data are available online at www.biolreprod.org). These results indicate that Dex reduces LXA 4 levels in placenta by inhibiting ALOX15 and ALOX15B.
Metabolism of AA via PTGS pathway also generates a series of lipid mediators involved in inflammatory processes. We found that Dex dose-dependently downregulated Ptgs1 mRNA (Fig. 6A) , whereas it upregulated Ptgs2 mRNA at the dose of 10 mg/kg ( Fig. 6B; P , 0.05) . Moreover, Dex upregulated expression of the thromboxane A synthase 1 (Tbxas1) gene, whereas it failed to alter prostacyclin synthase (Ptgis) mRNA levels (Supplemental Fig. S2, A and B) . With ELISA, we found that Dex significantly increased placental PGE 2 production (Fig. 6C) . These results suggest that the PTGS and ALOX pathways are differentially regulated by Dex in placenta.
LXA 4 Inhibits Dex-Mediated Sensitization of Placental Inflammation
To determine whether LXA 4 supplementation could prevent Dex-mediated sensitization of LPS-triggered placental inflammation, we injected LXA 4 (10 lg/kg) i.p. after Dex administration (see Dex 24 h pre-LPS 1 0 and Dex 24 h pre-LPS 2 0 in Fig. 7A ). LXA 4 significantly attenuated potentiated neutrophil infiltration compared to Dex plus LPS in both the Dex 24 h pre-LPS 1 0 ( Fig. 7B ; P , 0.05) and Dex 24 h pre-LPS 2 0 ( Fig. 7C ; P , 0.05) experiments. In Dex 24 h pre-LPS 1 0 , LXA 4 significantly suppressed the potentiated genes Il1b (P , 0.001) and Tnfa (P , 0.01) but not Il6, in response to LPS, compared to Dex plus LPS (Fig. 7D) . In Dex 24 h pre-LPS 2 0 , LXA 4 significantly inhibited Dex-mediated potentiation of LPS-induced Il1b (P , 0.05), Il6 (P , 0.01), and Tnfa (P , 0.05) expression compared to Dex plus LPS (Fig. 7E) . However, LXA 4 treatment did not alter basal or LPS-induced expression of proinflammatory cytokines in either the Dex 24 h pre-LPS 1 0 or Dex 24 h pre-LPS 2 0 experiment (Fig. 7, D and E). Additionally, LXA 4 administration did not alter Il10 expression compared to Dex plus LPS in Dex 24 h pre-LPS 1 0 (Fig. 7D) , whereas it significantly increased Il10 expression compared to that in Dex plus LPS in Dex 24 h pre-LPS 2 0 ( Fig.  7E ; P , 0.05).
We next used Western blotting to address whether LXA 4 could downregulate Dex-mediated enhancement of LPStriggered MAPKs and NF-jB. Indeed, LXA 4 supplementation 
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consistently attenuated Dex-mediated potentiation of LPSstimulated MAPKs and NF-jB in both the Dex 24 h pre-LPS 1 0 (Fig. 8, A and B) and Dex 24 h pre-LPS 2 0 (Fig. 8, C and D) experiments. Together these results demonstrate that LXA 4 inhibits Dex-mediated magnification of LPS-induced proinflammatory response.
LXA 4 Inhibits Dex-Mediated ALOX5 Activation both In Vivo and In Vitro
Because Dex significantly increased ALOX5 expression and nuclear translocation and enhanced LTB 4 production in placenta, we wondered whether LXA 4 could prevent Dexmediated activation of ALOX5. As expected, we found that LXA 4 suppressed Dex-enhanced ALOX5 protein expression (P , 0.001) and nuclear translocation (P , 0.05) in placenta (Fig.  9A) . IHC results further confirmed that LXA 4 inhibited Dexinduced ALOX5 upregulation and nuclear translocation in placental trophoblasts (Fig. 9B) . Accordingly, LXA 4 also blunted Dex-stimulated LTB 4 in placenta ( Fig. 9C ; P , 0.05).
Furthermore, Dex significantly enhanced ALOX5 expression and nuclear translocation in the HTR8/SVneo human trophoblast cell line in vitro, with a maximal enhancement observed at 1 lM (Fig. 10, A and B) . As expected, LXA 4 significantly suppressed Dex-mediated ALOX5 upregulation and nuclear translocation in HTR8/SVneo cells (Fig. 10, C and  D) . Of note, this inhibitory effect of LXA 4 could not be reversed by Boc2, antagonist to LXA 4 classic receptor FPR2/ ALX (Fig. 10, C and D) . In addition, the GC receptor (GR) antagonist RU486 blocked Dex-mediated ALOX5 activation in HTR8/SVneo cells (Fig. 10, C and D) , suggesting the involvement of GR in the effect of Dex on ALOX5. Together these results demonstrate that LXA 4 inhibits Dex-induced ALOX5 activation both in vivo and in vitro.
DISCUSSION
Inflammation dysregulation in placenta may lead to an extended clinical spectrum of pregnancy complications. Previous studies have shown that GCs and stress exhibit potent proinflammatory properties in brain and peripheral blood under some circumstances [9, 11, 12] , whereas whether and how GCs potentiate placental inflammatory responses remain unknown. In the present study, we demonstrated for the first time that Dex sensitized placental proinflammatory response to peritoneal immune challenge (LPS) via inhibition of LXA 4 biosynthesis. Timing of the relationship between GCs and LPS administration determines the proinflammatory or anti-inflammatory role of GCs in placenta. It is noteworthy that LPS-induced neutrophil infiltration and proinflammatory cytokine expression were decreased significantly at late endpoint, suggesting a resolution program. However, Dexpotentiated proinflammatory response failed to return to the same level as that in the LPS group at this juncture, indicating a delayed resolution in placenta caused by GC exposure during pregnancy. Our results provide a molecular basis for the Dexmediated proinflammation effect in placenta and evidence that LXA 4 counter-regulated Dex-sensitized placental inflammation as well as suppressed Dex-stimulated ALOX5 activation both in vivo and in vitro.
NF-jB pathway is associated with placental inflammation [27] . We reported recently that LPS increased proinflammatory cytokines production and NF-jB activation in trophoblast cell [18] . Also, LPS-induced proinflammatory cytokine production in trophoblast cells involves MAPKs [28] . In the present investigation, we showed that LPS significantly increased the expression levels of p-ERK, p-P38, p-JNK, p-IKKa/b, p-IjBa, and NF-jB p65 and reduced IjBa expression in placenta, consistent with above findings. Dex pretreatment failed to attenuate the effect of LPS on MAPKs and NF-jB at both short and late endpoints. In contrast, Dex further augmented LPSinduced activation of MAPKs and NF-jB at late endpoint. These results indicate that Dex-mediated enhancement of LPSstimulated MAPKs and NF-kB may give rise to placental inflammatory dysregulation and further pregnancy disorders.
LXA 4 is a potent anti-inflammatory and proresolving lipid mediator derived from AA via transcellular biosynthesis. It was reported earlier that circulating levels of LXA 4 significantly increased throughout human pregnancy [17] , indicating a potential role for LXA 4 in the maintenance of pregnancy homeostasis. We recently showed that LXA 4 could inhibit LPS-stimulated proinflammatory cytokine production and NFjB activation in trophoblast cells [18] . Because GCs inhibit release of their AA precursor, Dex should be able to blunt the biosynthesis of downstream lipid mediators, including LXA 4 . Indeed, we showed here that Dex reduced basal LXA 4 levels in placenta in a dose-dependent pattern. Moreover, Dex pretreatment significantly attenuated LPS-induced LXA 4 production at late endpoint. Taken together, Dex reduced placental LXA 4 , resulting in the sensitization of placental proinflammatory response.
In the present study, we identified the expression of ALOX5, ALOX15, ALOX15B, and ALOX12 in rat placenta, suggesting placenta as the site of LXA 4 biosynthesis. Dex inhibited both ALOX15 and ALOX15B expression, whereas it activated ALOX5. ALOX5 is the key enzyme in both LT and LX biosynthesis. Upon stimulation, it translocates to the nuclear membrane to form an enzyme complex which converts AA to LTs [29] . Activation of ALOX5 but inhibition of ALOX15 and ALOX15B by Dex suggest possible class switching from LX to LT production. Here, we indeed found that Dex-mediated placental ALOX5 activation contributed to enhanced LTB 4 but not to LXA 4 biosynthesis in placenta. LTs are potent mediators of both pro-oxidant and proinflammatory reactions [30] . Hence, ALOX5 activation by Dex may represent a priming factor in placenta, where subsequent exposure to inflammation stimuli (e.g., LPS) leads to an exacerbated inflammation. As described above, ALOX12 is also a biosynthesis enzyme for LXA 4 , which has been further confirmed by our previous report that platelet-derived microparticles can transfer ALOX12 to LT-producing mast cells for LXA 4 biosynthesis [31] . Unexpectedly, Dex upregulated   FIG. 4 . Dex inhibits placental LXA 4 production. A) Effect of Dex is shown on basal LXA 4 levels in placenta. Rats were treated with Dex as described in Animal protocol 2. Data are means 6 SEM from n ¼ 6 rats. *P , 0.05 and **P , 0.01 versus control group; one-way ANOVA with S-N-K posttest. B and C) Effect of Dex is shown on LPS-induced LXA 4 production in placenta. Rats were treated with Dex and LPS as described in Dex 24 h pre-LPS 1 of Figure 1A and Dex 24 h pre-LPS 2 of Figure 2A . B) The effect in Dex 24 h pre-LPS 1. C) Effect in Dex 24 h pre-LPS 2. LXA 4 levels were detected with ELISA. Results are means 6 SEM from n ¼ 6 rats. *P , 0.05, ***P , 0.001, one-way ANOVA with S-N-K posttest. DC, vehicle for Dex; LC, vehicle for LPS.
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placental ALOX12 expression, suggesting a differential pattern for modulation of ALOXs by Dex in placenta.
We also examined the effects of Dex on Ptgs1, Ptgs2, Ptgis, and Tbxas1expression and PGE 2 production in placenta. Dex downregulated Ptgs1 mRNA at all doses, whereas it upregulated Ptgs2 mRNA only at 10 mg/kg, which is different from two previous reports in vitro [32] and in vivo [10] that are also contradictory. This phenomenon may be due to differential spatial and temporal conditions or dose of Dex treatment. Nevertheless, we showed here that Dex increased proinflammatory PGE 2 levels in placenta, which is consistent with the above two reports [10, 32] as well as with another study in placenta trophoblasts [33] . In addition, we showed that Dex upregulated expression of the Tbxas1 gene, whereas it failed to alter Ptgis mRNA levels. Thromboxane A 2 (TXA 2 ) has been shown to enhance cellular immune responses and inflammatory tissue injury [34] , and TXA 2 -PGI 2 imbalance contributes to the onset of clinical symptoms of PE [35] . Thus, the increased PGE 2 production and TXA 2 -PGI 2 imbalance suggest another novel mechanism for Dex-mediated sensitization of placental inflammation.
In the present study, LXA 4 supplementation counterregulated Dex-mediated potentiation of placental proinflammatory response. LXA 4 also partially reversed Dex-mediated suppression of anti-inflammatory Il10 expression, representing the proresolving actions of LXA 4 . Moreover, the effect of counter-regulation of LXA 4 on Dex-mediated placental ALOX5 activation and LTB 4 production in placenta was FIG. 5 . Dex disturbs LXA 4 biosynthesis in placenta. Rats were treated with Dex as described in Animal protocol 2. A-C) Effect of Dex is shown on expression of placental genes Alox15, Alox15b, and Alox5. Gene expression was examined with real-time PCR. D) Effects of Dex are shown on expression of placental proteins ALOX15, ALOX15B, and ALOX5 and on ALOX5 nuclear translocation. Protein expression and ALOX5 nuclear translocation were detected by Western blotting, and relative densitometric quantification for protein bands is also shown. E) Effect of Dex on ALOX5 expression and location in placenta tissue. IHC for ALOX5 was conducted using placenta paraffin sections. Original magnification 3400; bar ¼ 50 lm. F) Effect of Dex on basal LTB 4 levels in placenta. LTB 4 levels were detected with ELISA. Results are means 6 SEM from n ¼ 6 rats. *P , 0.05, **P , 0.01 and ***P , 0.001 versus control group; one-way ANOVA with S-N-K posttest. DC, vehicle for Dex.
ZHANG ET AL. A) The expression levels of total and nuclear ALOX5 in placenta were detected by Western blotting, and relative densitometric quantification for protein bands is also shown. B) IHC for ALOX5 was conducted with placenta paraffin sections. Original magnification 3400; bar ¼ 50 lm. C) Effect of LXA 4 on Dex-enhanced LTB 4 increase in placenta. LTB 4 levels were detected with ELISA. Results are means 6 SEM from n ¼ 6 rats. *P , 0.05, **P , 0.01, ***P , 0.001; one-way ANOVA with S-N-K posttest.
observed. Using HTR8/SVneo trophoblast cells, we also found that Dex enhanced ALOX5 expression and nuclear translocation in vitro, which was reduced by LXA 4 . However, this action of LXA 4 was not blocked by the presence of the FPR2/ ALX antagonist Boc2, suggesting LXA 4 inhibits ALOX5 activation independently of FPR2/ALX. A significant body of work attests to the fact that LXA 4 could either directly or indirectly activate various receptors, including FPR2/ALX, cysteinyl LT receptor, cannabinoid receptor, aryl hydrocarbon receptor, and estrogen receptor a (ERa) [25, [36] [37] [38] . We recently reported that LXA 4 blocked embryo implantation via controlling ERa activity, which involved the suppression of implantation-related inflammatory microenvironment [39] . Although there is no evidence suggesting direct interaction between LXA 4 and GR, receptor cross-talks exist. Increasing studies indicated that ER and GR are functionally integrated at the response elements of target genes promoter [40, 41] , which underlies the opposing actions of the two receptors on physiological responses. Another crosstalk between the activated forms of aryl hydrocarbon receptor and GR was also reported [42] . Here we found GR was required for ALOX5 activation, consistent with a previous work conducted in neurons [43] . We recently showed that LXA 4 analog partially alleviated Dex-induced IUGR in rats [7] , further supporting 
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, and 10 À8 M) for 24 hours. A) Total and nuclear ALOX5 expression levels in HTR8/SVneo cells were detected by Western blotting, and relative densitometric quantification for protein bands is also shown. B) Immunofluorescence was conducted for detecting ALOX5 expression and location in HTR8/SVneo cells. Original magnification 3200. C and D) LXA 4 counter-regulates Dex-mediated ALOX5 activation in HTR8/SVneo cells. HTR8/SVneo cells were treated with Dex (1 lM) or with Dex (1 lM) plus LXA 4 (200 nM), Boc2 (10 lM), or RU486 (5 lM) for 24 h. C) Expression levels of total and nuclear ALOX5 in HTR8/SVneo cells were detected by Western blotting, and relative densitometric quantification for protein bands is also shown. D) Immunofluorescence was conducted for determining ALOX5 expression and location in HTR8/SVneo cells. Original magnification 3200. Results are means 6 SEM from 3 independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001; one-way ANOVA with S-N-K posttest. DC, vehicle for Dex.
GLUCOCORTICOIDS SENSITIZE PLACENTAL INFLAMMATION
various counteraction of LXA 4 on GCs in vivo through unknown mechanisms. These results indicate that counterregulation of LXA 4 on Dex-induced inflammatory potentiation may be mediated through the complicated receptor interaction between GR and LXA 4 receptors.
In summary, we demonstrate for the first time the proinflammatory effects of GCs in rat placenta, which represent a paradigm shift in the current understanding of their roles in immune modulation and reveals partial immunologic mechanisms underlying latent side effect of GCs exposure on placenta. The inhibition of LXA 4 biosynthesis but enhancement of proinflammatory cytokines (e.g., Il1b and Tnfa) and eicosanoids (e.g., LTB 4 and PGE 2 ) by GCs represented key mechanisms contributing to inflammation imbalance in placenta. Based on these findings, this study proposes the molecular mechanisms underlying GC-mediated sensitization and exacerbation of rat placental inflammatory responses (Fig.  11) . Our results also provided the scientific basis for administration of exogenous LXA 4 as potential therapeutic strategy in prevention of excessive placenta inflammationrelated pregnancy complications. Together these findings partially elucidated the pathogenesis of GC-primed pregnancy disorders and might lead to the development of potential therapeutic strategy in prevention of GC exposure or stressrelated pregnancy complications, which will eventually contribute to the improvement of maternal and childrens' health.
